Cerebral, cancer and cardiovascular diseases are the leading causes of death in all developed countries. They cause physical and cognitive disabilities and more or less severe disabilities that directly affect the quality of life of the sick and their loved ones. The ageing of the population in developed countries makes these diseases increasingly burdensome for public health. Improving the care of people with these conditions depends directly on the emergence and diffusion of biomedical innovations from screening to treatment. The value of these innovations can only be scientifically demonstrated by the implementation of rigorous experimental and/or clinical research protocols. The real impact of recent pre-clinical and clinical innovations on improving the care of patients in real life is very poorly known and their impact on the organisation of care is poorly assessed. The few studies conducted in the general population show how the practice of care and the integration of innovations often escape the biomedical logic and depend on social, economic or geographical determinants.The development of supportive care, outpatient care, therapeutic education and the establishment of care networks and the increasing involvement of patients in their care have revealed and strengthened the close links between the occurrence and evolution of diseases and the environment of individuals in its family, social, economic and geographical dimensions. Psychological and sociological approaches, facilitated by the increasing involvement of user committees, have highlighted the need to take into consideration, around the place of "the caregiver, the patient’s family environment in order to optimise his or her care. Geographical and sociological approaches have shown how taking into account the characteristics of the place of residence and the socio-economic environment of patients is a major criterion in the success of the development of outpatient medicine and care networks. Recent examples of health planning, cancer plan, Alzheimer’s plan show how an integrative approach to evaluating innovations, from proof of concept to measuring efficiency is essential to optimising care practices, managing financial resources in an increasingly constrained context, and ensuring social equity. On the Nord Caennais plateau there is recognised expertise in the fields of neuroscience and oncology through world-class research teams, certified by major national bodies (CNRS, INSERM, CEA), supported by state-of-the-art regional infrastructures (CYCERON — IBISA platform for in vivo imaging-, CURB — IBISA research platform on strokes (ESRP)-, SFR ICORE technical platforms), on a remarkable coverage of the territory by morbidity registers; the whole in close relations with the health centres (CHU de Caen and Centre François Baclesse). Innov@ReT is part of the more global INNOVONS project that will consolidate a coherent set that promotes pre-clinical and clinical investigations in the field of screening and functional explorations in neurology, cancer and cardiology. Innov@ReT focuses on the translational aspect of research ranging from cell biology to imaging in humans. This new tool will benefit existing and future EPST structures, the University’s host teams. In addition to providing these research units with the tools for their development and interface with the clinic, it would be the place for common methodological developments.